Pacira Pharmaceuticals Return on Equity:
-80.11% for Dec. 31, 2012Pacira Pharmaceuticals Historical Return on Equity Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | -80.11% |
| Sept. 30, 2012 | -93.35% |
| June 30, 2012 | -103.7% |
| March 31, 2012 | -148.1% |
| Dec. 31, 2011 | -319.4% |
About Return on Equity (ROE)
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities).
ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
PCRX Return on Equity Benchmarks
| Companies | |
|---|---|
| BioScrip | 24.85% |
| Neurocrine Biosciences | -4.22% |
| Lannett Company | 7.98% |
PCRX Return on Equity Rankings
| Overall |
45th percentile 4336 of 8002 |
| Sector |
40th percentile 410 of 684 in Healthcare |
| Industry |
48th percentile 28 of 54 in Drug Manufacturers - Major |
PCRX Return on Equity Range, Past 5 Years
| Minimum | -319.4% | Dec 2011 |
| Maximum | -80.11% | Dec 2012 |
| Average | -148.9% |
PCRX News
Pacira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 8
Seeking Alpha May 8
